Back to top

messenger-rna: Archive

Zacks Equity Research

NVAX Stock Surges on Securing FDA Approval for COVID-19 Vaccine

The FDA grants full approval to Novavax's protein-based COVID-19 vaccine after nearly a two-month delay, albeit with some new conditions.

SNYPositive Net Change PFEPositive Net Change MRNAPositive Net Change NVAXNegative Net Change

Zacks Equity Research

Moderna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1

Moderna plans to launch 10 new marketed products over the next three years, aiming to diversify a revenue base, which is still heavily reliant on COVID-19 vaccine sales.

GSKPositive Net Change PFEPositive Net Change MRKPositive Net Change MRNAPositive Net Change

Zacks Equity Research

Moderna Beats on Q1 Earnings, Lags on Revenues, Focuses on Cost Cuts

MRNA reports mixed Q1 results. The company reiterates 2025 sales guidance but announces a cost-cutting initiative to reduce expenses significantly by 2027.

GSKPositive Net Change PFEPositive Net Change MRKPositive Net Change MRNAPositive Net Change

Zacks Equity Research

Can Moderna Keep the Beat Streak Alive This Earnings Season?

When MRNA reports first-quarter earnings, investors will likely focus on pipeline updates.

MRKPositive Net Change MRNAPositive Net Change CTMXNegative Net Change ARGXPositive Net Change

Zacks Equity Research

VRTX Secures Nod for Expanded Use of CF Drug Kaftrio in Europe

With the latest approval, Vertex's Kaftrio is now eligible to treat about 4,000 people living in the EU with rare mutations of cystic fibrosis.

VRTXPositive Net Change MRNAPositive Net Change ANIPPositive Net Change ETNBPositive Net Change

Sundeep Ganoria

Biotech Stocks Fall After Top FDA Official Quits Over Clash With RFK Jr.

The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.

MRNAPositive Net Change NVAXNegative Net Change SRPTPositive Net Change CRSPPositive Net Change PCVXPositive Net Change